SCHEMBL3233192

SCHEMBL3233192

CCCCCC(NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CTSK P43235 8/20 0.62
CTSS P25774 3/20 0.62
NOD1 Q9Y239 1/20 0.49
ALDH1A1 P00352 1/20 0.48
TSHR P16473 1/20 0.48
MEN1 O00255 1/20 0.47
GAA P10253 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18875931 1.00 CTSK (0.62) CTSKCTSSNOD1ALDH1A1TSHR
SCHEMBL14820490 1.00 CTSK (0.62) CTSKCTSSNOD1ALDH1A1TSHR
SCHEMBL1926493 0.98 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL7839929 0.98 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL2706071 0.98 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL7555645 0.98 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL7547359 0.98 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL5050858 0.98 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL7555646 0.98 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL7550258 0.98 CTSK (0.60) CTSKCTSSNOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713321-A1 PROTACS FOR ASK1 PROTEIN DEGRADATION: PREPARATION AND USE THEREOF Council of Scientific and Industrial Research (IN) 2026-03-25 EP disclosed
US-20250114350-A1 INHIBITORS OF PRENYLTRANSFERASES AS ANTIFUNGAL AGENTS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2025-04-10 US disclosed
WO-2024236595-A1 PROTACS FOR ASK1 PROTEIN DEGRADATION: PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2024-11-21 WO disclosed
CN-118525021-A MALT 1-targeted proteolytic compounds 上海齐鲁制药研究中心有限公司 2024-08-20 CN disclosed
EP-3040417-B1 MACROCYCLIC PEPTIDE, METHOD FOR PRODUCING SAME, AND SCREENING METHOD USING MACROCYCLIC PEPTIDE LIBRARY UNIV TOKYO (JP) 2023-12-13 EP disclosed
US-11801306-B2 Compositions and methods for targeted RNA delivery VERVE THERAPEUTICS, INC. (US) 2023-10-31 US disclosed
CN-112174960-B Toll-like receptor modulating 4, 6-diamino-pyrido [3,2-D ] pyrimidine compounds 吉利德科学公司 2023-10-10 CN disclosed
WO-2023061440-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2023-04-20 WO disclosed
CN-112174960-A Toll-like receptor modulating 4, 6-diamino-pyrido [3,2-D ] pyrimidine compounds 吉利德科学公司 2021-01-05 CN disclosed
CN-107108615-B Toll-like receptor modulating 4, 6-diamino-pyrido [3,2-D ] pyrimidine compounds 吉利德科学公司 2020-11-20 CN disclosed
US-20110300174-A1 CONJUGATES FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION PFIZER VACCINES LLC (US) 2011-12-08 US disclosed
US-8063101-B2 Carotenoid analogs and derivatives for the prevention of platelet aggregation CARDAX PHARMACEUTICALS, INC. (US) 2011-11-22 US disclosed
US-20100286365-A1 PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME AMYLIN PHARMACEUTICALS, INC. (US) 2010-11-11 US disclosed
EP-2190845-A2 HDAC INHIBITORS ArQule, Inc. (US) 2010-06-02 EP disclosed
WO-2009026446-A9 HDAC INHIBITORS ARQULE, INC. (US) 2010-03-11 WO disclosed
US-20090124574-A1 Carotenoid analogs and derivatives for the prevention of platelet aggregation CARDAX PHARMA, INC. 2009-05-14 US disclosed
US-20090099061-A1 SYNTHESIS OF CAROTENOID ANALOGS OR DERIVATIVES WITH IMPROVED ANTIOXIDANT CHARACTERISTICS CARDAX PHARMACEUTICALS, INC. 2009-04-16 US disclosed
WO-2009026446-A2 HDAC INHIBITORS ARQULE, INC. (US) 2009-02-26 WO disclosed
US-4189606-A ABOSTIFACIENT GRUPPO LEPETIT S.P.A. (IT) 1980-02-19 US disclosed
US-4182903-A ABOSTIFACIENTS GRUPPO LEPETIT S.P.A. (IT) 1980-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114350-A1 INHIBITORS OF PRENYLTRANSFERASES AS ANTIFUNGAL AGENTS FNTA, FNTB, FDPS CTSK 3350/4885CTSS 2733/4885NOD1 1519/4885
US-20110300174-A1 CONJUGATES FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION CHRNG, CHRND, CHRNA3 CTSK 4012/4885CTSS 4095/4885NOD1 402/4885
US-20090124574-A1 Carotenoid analogs and derivatives for the prevention of platelet aggregation PROC, PFKP, PF4 CTSK 4132/4885CTSS 4141/4885NOD1 3064/4885
US-20090099061-A1 SYNTHESIS OF CAROTENOID ANALOGS OR DERIVATIVES WITH IMPROVED ANTIOXIDANT CHARACTERISTICS CAT, HBZ, POLL CTSK 2618/4885CTSS 2222/4885NOD1 2088/4885
US-11801306-B2 Compositions and methods for targeted RNA delivery PCSK9, LDLR, PCSK7 CTSK 453/4885CTSS 738/4885NOD1 3484/4885
US-20100286365-A1 PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME DNPEP, PEPD, VIP CTSK 145/4885CTSS 197/4885NOD1 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.